WillItSurvive
Pharma and healthcare groups · United States

Pfizer

pfizer.com ↗

Pfizer makes and sells FDA approved drugs and vaccines across major disease areas worldwide.

Hard to displace
Assessed 20 July 2026 · Evidence as of 20 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 20 July 2026 · Checkable from 2026-2027 · Every call on the record Checkpoint: Berobenatide (MET-097i) obesity Phase 3 readout
The call

Pfizer's regulatory and manufacturing base keeps it standing, but Lilly's obesity lead and the Eliquis patent cliff are testing how much growth is left.

Pfizer is a drug and vaccine company that sells prescription medicines, over-the-counter drugs, and vaccines to hospitals, pharmacies, and governments. It is hard for competitors or new companies to copy because the U.S. Food and Drug Administration (FDA) takes years to approve new medicines, Pfizer owns factories that meet strict safety rules, and it has long-term contracts with insurance companies and Medicaid that lock in customers. Eli Lilly is winning market share with obesity drugs right now, but Pfizer's real test is whether its new obesity medicine works well enough in late-stage trials in 2026 and 2027; if that fails and one of its top-selling blood thinner (Eliquis) loses patent protection, the company may have to cut the money it pays back to shareholders.

Why
01
AI pressure: None apparent. AI speeds up drug discovery inside Pfizer's own labs more than it threatens the business from outside. Could AI do the core job? Unlikely.
02
Bigger players: Eli Lilly. Lilly's Zepbound and obesity pipeline are pulling ahead while Pfizer's own oral GLP-1 attempts have failed or lagged. Could a giant copy it? No, they are blocked.
03
What protects it. FDA approvals, GMP-certified plants, and long-term payer contracts that no new entrant can copy quickly.
What would change this call
Berobenatide/MET-097i Phase 3 readout (2026-2027). Whether Pfizer's obesity pipeline can compete with Lilly's Zepbound and Novo's Wegovy.
Eliquis sales trend through FY2026 quarterly reports. Whether the ~$1.5B loss-of-exclusivity hit tracks guidance or worsens as generics enter.
Outcome of Arbutus/Genevant mRNA-LNP patent suits in Canada and Europe UPC. Whether litigation forces damages or injunctions affecting Comirnaty sales.
Key numbers
  • FY2025 revenue $62.58B, down ~2% YoY (2025-12-31)
  • Eliquis loss of exclusivity cuts ~$1.5B in 2026 (2026-07-01)
  • Dividend yield ~6.8%, payout ratio over 130% of EPS (2026-07-17)
Named risks
  • Eliquis loss-of-exclusivity in 2026 cutting roughly $1.5B from revenue. Severity: high
  • Dividend payout ratio over 130% of trailing EPS raises sustainability concerns. Severity: high
  • Obesity pipeline (berobenatide/MET-097i) trailing Lilly's Zepbound in Phase 2 data. Severity: medium
  • Expanding international mRNA-LNP patent litigation from Arbutus/Genevant. Severity: medium
  • Ongoing headcount reductions and manufacturing site layoffs through 2026. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Eli Lillylosing toLilly hit $65.2B 2025 revenue (+45%) and ~$1.1T market cap on obesity drugs vs Pfizer's late Metsera entry, 2026-04-20
Novo Nordisklosing toOutbid Pfizer in Metsera acquisition talks before Pfizer won the deal in Sept 2025
Johnson & Johnsonlosing toJ&J posted $94.2B 2025 revenue, largest among Big Pharma, ahead of Pfizer's $62.58B
Bristol Myers SquibbcontestingCo-markets Eliquis, jointly facing 2026 patent cliff pressure with Pfizer
Arbutus Biopharma/GenevantcontestingFiled expanded mRNA-LNP patent suits against Pfizer/BioNTech, reported 2026-07-20
GSK, SanoficontestingDirect vaccine-market rivals to Pfizer's Prevnar and Comirnaty franchises
Questions people ask
Is Pfizer profitable in 2026?
Yes. Pfizer guided FY2026 revenue of $59.5B to $62.5B with adjusted diluted EPS of $2.80 to $3.00, and Q1 2026 revenue hit $14.45B, up 5.4% YoY, beating consensus, as reported May 5, 2026.
Is Pfizer laying off workers in 2026?
Yes. Pfizer plans over 100 job cuts (12% of the site) at its Ringaskiddy, Ireland manufacturing plant in Q4 2026, part of a broader cost program that has cut roughly 1,700+ jobs across Ireland, UK and US sites since 2023.
Could AI replace Pfizer's drug discovery work?
No. AI models like Boltz-2 and Chai-3, licensed by Pfizer in January and June 2026, accelerate molecule design but Pfizer retains full IP ownership and still controls the FDA-regulated trials, GMP manufacturing and liability infrastructure no AI model can substitute for.
Who is Pfizer's biggest competitor?
Eli Lilly, which surged to roughly $65.2B in 2025 revenue (up 45%) and an approximately $1.1 trillion market cap on obesity-drug dominance, directly threatening Pfizer's late entry into the GLP-1 obesity market via its 2025 Metsera acquisition.
Does Pfizer own the Metsera obesity drug pipeline?
Yes. Pfizer completed its acquisition of clinical-stage obesity biotech Metsera on November 13, 2025 for an enterprise value of roughly $7 to $10 billion, gaining lead asset MET-097i (berobenatide), now in Phase 3 trials.
Is Pfizer's dividend at risk?
It carries elevated risk. As of July 17, 2026, Pfizer's dividend yields about 6.8-6.9% with a payout ratio exceeding 130% of trailing EPS, meaning sustainability depends on pipeline results, especially the berobenatide obesity trials.
Timeline
  • 2026-07-20Arbutus/Genevant expand mRNA-LNP patent suits against Pfizer/BioNTech across Canada and Europe
  • 2026-06-04Pfizer licenses Chai Discovery's Chai-3 antibody design AI model
  • 2026-05-05Q1 2026 revenue reported at $14.45B, up 5.4% YoY, beating consensus
  • 2026-05-01Vepdegestrant (PROTAC drug with Arvinas) approved for breast cancer
  • 2026-04-22Pfizer announces over 100 job cuts at Ringaskiddy, Ireland plant for Q4 2026
  • 2026-02-03Metsera Phase 2 obesity data shows drug slightly inferior to Lilly's Zepbound
  • 2026-01-08Pfizer announces strategic AI collaboration with Boltz PBC
  • 2025-11-13Pfizer completes acquisition of Metsera for $7-10B enterprise value
  • 2025-09-30Pfizer signs landmark MFN drug pricing deal with Trump administration
  • 2025-04-01Pfizer discontinues in-house oral GLP-1 danuglipron over liver toxicity
Revision history
20 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Vertex PharmaceuticalsTenet HealthcareIntuitive Surgical
More in Pharma and healthcare groups →
Sources